Figure 2From: Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patientsPatient benefit from HIPEC. In the HIPEC group, 2- and 5-year survival rates were each 72.5%, compared to patients with CRS only (CC3 score excluded) with 2- and 5-year survival rates at 52.0% and 38.3%, respectively (N = 70; P = 0.043).Back to article page